Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious

Simply Wall StMar 8 07:33

Oriental Biotech (688298.SH): Stock repurchases have not been implemented

Gelonghui March 1 | Oriental Biotech (688298.SH) announced that as of the disclosure date of this announcement, the company had not implemented a stock repurchase.

Gelonghui FinanceMar 1 16:54

Oriental Biotech (688298.SH): Net loss of 404 million yuan in 2023

Gelonghui, Feb. 28: Oriental Biotech (688298.SH) announced the 2023 Annual Results Report. In 2023, the company achieved total operating revenue of 824.128 million yuan, a decrease of 90.60% over the previous year; net profit attributable to the owner of the parent company after deducting non-recurring profit and loss - RMB 404.472,500, a decrease of 119.36% over the previous year.

Gelonghui FinanceFeb 28 19:02

Express News | Oriental Biotech: Plans to buy back shares for 50 million yuan to 100 million yuan

BreakingsFeb 7 16:13

Express News | More than 30 listed companies announced plans to repurchase or increase their holdings by up to 100 million yuan after the market and announced that the controlling shareholders of Tongwei Co., Ltd. intend to increase their holdings by up to 2 billion yua

BreakingsJan 31 22:46

Express News | Oriental Biotech: The actual controller proposed to buy back shares for 50 million yuan to 100 million yuan

BreakingsJan 31 17:26